Kneel down and beg for immunohistochemistry analysis of breast ductal cancer!

Breast cancer is a CAF regimen. Plus hormones**.

This result is good, please add the age, pathological stage, and current patient condition.

Generally, the number of chemotherapy treatments is determined according to the patient's physical condition and condition. Doctors usually use a regimen of 6 chemotherapy sessions. Special circumstances may be handled as appropriate.

ER estrogen receptors, PR progesterone receptors: usually this type of laboratory is the most common and important. They determine whether the tumor is hormone-sensitive, and also play an important role in prognostic assessment.

There are ER and PR in normal breast epithelial cells. When cells become cancerous, ER and PR are partially and completely missing. If the cells still retain ER and/or PR, the growth and proliferation of this breast cancer cell is still regulated by endocrine and is called hormone-dependent breast cancer; If ER and/or PR are missing, the growth and proliferation of this breast cancer cell is no longer regulated by endocrine and is called hormone-independent breast cancer.

Immunohistochemistry assay C-ERBB2 oncogene: low expression in normal breast tissue, can increase in breast cancer tissue, its expression is positively correlated with breast cancer grade, lymph node metastasis and clinical stage, the higher the expression rate, the worse the prognosis may be. C-ERBB2 usually requires FISH to confirm whether HER2 is a true positive.

KI-67: typically associated with the rate of tumor growth; Associated with prognosis in patients with negative breast cancer, particularly lymph node metastases, to determine the use of adjunctive chemistry**. p53 gene:

Breast cancer cells with high p53 mutation rate have strong proliferative activity, poor differentiation, high malignancy, aggressiveness and high lymph node metastasis rate.

The immunohistochemistry results of breast cancer are still relatively reliable, so what is the analysis of the immunohistochemistry results of breast cancer and the first time?

Immunohistochemistry of breast cancer is of great significance for the staging and prognosis of breast cancer. The analysis of the results of immunohistochemistry of breast cancer is mainly carried out from the following aspects, one is hormone receptors, including estrogen receptor ER and progesterone receptor PR. Receptor expressing (+) requires endocrine **, such as tamoxifen, letrozole, alatrozole, etc.

There is also the human epidermal growth factor-2 receptor, which is positively expressed, has a relatively poor prognosis and requires the use of targeting**. and ki-67, with high expression of ki-67, implying a poor prognosis.

Among them, patients with basal cell breast cancer are all negative for ER, PR, and HER2, and 75% of patients will have TP53 mutations, as well as BRCAI (tumor suppressor gene) mutations, and Ki-67 is negative for acorn. This type of breast cancer is 85% triple-negative breast cancer and has a shorter survival period than other types.

Hello, considering the situation described above, it is recommended that patients use the latest tumor technology specific anti-tumor immunity, which is non-toxic, non-invasive, effectively improves the patient's immunity, and can also control the metastasis of the disease. Hope it helps.

Question: Can you tell if it is highly differentiated or underdifferentiated?

Solid adenocarcinoma is poorly differentiated.

Acinar and adherent are highly differentiated.

Question: Is the problem of low differentiation more serious than the problem of high differentiation?

Spread faster, huh?

Question: In a case like the one I posted, I have undergone surgery, chemotherapy and radiotherapy, is it possible to follow up**?

Two metastases have been seen in 11 groups of lymph nodes.

Question: Is this early, middle, or late?

Wait a minute, I'll take a look.

According to the information you have given so far, the only regrettable thing is that the lump is larger, and the immunohistochemistry is quite ideal.

Immunohistochemistry of breast cancer mainly depends on the expression results of ER, PR, CEB-2 and KI67.

ER and PR are hormone receptor manifestations, with a high positive rate, good, with medicine to eat, sensitive to endocrine **.

CEB-2 anti-cancer gene test, negative. Good, low rate of transfers.

P53 negative, good, low metastasis** rate.

ki67, cancer cell proliferation effect detection, 15% is not bad.

T2N0M0 stage IIA stage.

The first chemotherapy had white blood cells that were so low. Or a change of option should be considered.

The others basically agree with the professional views of Qishi 1983.

There are a lot of chemoradiotherapy, and it is necessary to do further to prevent the occurrence of complications or sequelae After understanding the situation in detail, I will help you analyze the relevant Q chat.

Immunohistochemistry root lymph nodes have little to do with it.

ER and PR are estrogen and progesterone receptors, and positive results indicate that the tumor is hormone-dependent and sensitive to endocrine, that is, oral tamoxifen, anastrozole, letrozole, toremifene and so on.

CERBB-2, which is a genetic level test, is sensitive to biological ** when it is strong positive, and represents the drug, Herceptin, which is expensive and cannot be borne by ordinary families.

If there is nothing special in the patient's condition, it is recommended to insist on taking tamoxifen for 5 years, 10mg, 2 times a day; Endometrial ultrasound should be repeated every six months.

The condition of lymph nodes is in the macropathology, not in immunohistochemistry. So wonder no more!

It can be combined with traditional Chinese medicine**, on the one hand, conditioning, on the other hand**.

Immunohistochemistry is only an indicator of antigen and antibody response, did the patient do pathological examination after surgery? Add q to help you analyze the relevant inspection report in detail.

C-ERBB-2 as the target of breast cancer** strategy C-ERBB-2 is closely related to the occurrence and development of breast cancer, and is an important molecular marker and target of breast cancer. In-depth research into the signal transduction mechanisms of the ERBB family has opened up a broad path for breast cancer targeting**, the most successful example of which is the targeting of C-..

If the size of the lump is small and no cancer metastasis is seen, it is considered to be stage 1 breast cancer, that is, early stage;

The tissue grade was grade 2, indicating poor differentiation and strong invasion and metastasis ability.

ER-A positive, suitable for endocrine**;

Moderate positive KI-67 indicates that cancer cells are more active in proliferation and require systemic chemotherapy after surgery.

Negative FISH, suggesting no need for targeting**;

If breast-conserving surgery is performed, whole-breast radiotherapy should also be combined;

Based on the above pathological results, it is considered to be Luminal B breast cancer, and the comprehensive effect is better, especially the early stage, the 10-year survival rate is high, and there is a possibility of ***.

VEGF (+) 80%, vascular endothelial growth factor family; It is thought to be a factor that plays an important role in the formation of neovascularization in most tumors; Provides a more convenient pathway for tumor cells to metastasize to regional lymph nodes.

EGFR (+) 80%, which is a transmembrane glycoprotein; It plays an important role in the occurrence and development of malignant tumors; It has become an important target for molecular targeting.

ER(-) estrogen receptor, PR(-) progesterone receptor, C-ERBB-2 (++80%, carcinoembryonic antigen.

p53(+)70%；Commonly known as molecular police, the detection is mutated, and the higher the better.

MDR(-) tumor multidrug resistance; Presence often leads to chemotherapy failure.

e-ead(+) This should be e-cad; e-cadherin, the gene of e-cadherin plays an important role in maintaining cell morphology and regulating intercellular adhesion. In recent years, studies have shown that the occurrence and development of a variety of tumors and their biological characteristics are related to the abnormal and low expression of e-CAD and -cat.

topoii(-) topoisomerase ; Chemotherapy is less effective with topoisomerase II (TOPOII) inhibitors.

gst-n(-)gst-π；markers of multidrug resistance; It can also be used as one of the marker enzymes for tumor tissue differentiation, lymph node metastasis and cell proliferation studies.